Alloy Therapeutics Unveils siRNA Platform Targeting Delivery Beyond the Liver
Key Points
- Alloy launched TEMPER, a proprietary siRNA platform designed to deliver RNA therapeutics to tissues beyond the liver.
- The modular platform combines siRNA design, proprietary chemistry and lipid conjugate targeting for skeletal and cardiac muscle, with potential CNS applications.
- TEMPER joins Alloy's AntiClastic ASO and antibody-oligonucleotide conjugate capabilities in its integrated genetic medicines offering.
Alloy Therapeutics has expanded its genetic medicines portfolio with the launch of TEMPER™ (Targeted Extra-Hepatic Modular Precision-Engineered RNA), a proprietary small interfering RNA (siRNA) platform aimed at overcoming one of the major obstacles in RNA drug development: delivering therapeutics to tissues outside the liver. The Boston-based biotechnology company says the platform incorporates delivery technology obtained through a strategic transaction with Transcera, adding a new capability to its existing RNA discovery and development services.
Although siRNA has emerged as a promising approach for selectively regulating gene expression, delivery beyond the liver remains a significant technical challenge. Reaching tissues such as skeletal muscle and the heart, in particular, has been difficult to achieve at therapeutically meaningful levels. TEMPER is intended to address these limitations through a combination of differentiated siRNA design, proprietary chemical modifications and targeted delivery technologies.
“Targeted delivery is one of the most important opportunities in RNA medicines today, and we see tremendous potential to expand what is possible beyond the liver,” says Errik Anderson, founder and CEO of Alloy Therapeutics. He notes that combining RNA design and delivery capabilities could help collaborators pursue biological targets and disease indications that have historically been difficult to access.
TEMPER is being developed as a modular technology platform that brings together siRNA design, proprietary chemistry and tissue-targeting strategies. Its architecture is intended to support the development and optimization of RNA-based therapeutics across a broader range of tissues.
A central element is a proprietary lipid conjugate technology designed to facilitate delivery to extrahepatic tissues, including skeletal and cardiac muscle. The platform is also being developed to accommodate additional targeting strategies, such as antibody-oligonucleotide conjugates (AOCs), which could provide opportunities to extend siRNA delivery into the central nervous system (CNS) and other tissues.
Alloy plans to evaluate the technology through preclinical research examining tissue distribution, functional gene knockdown and delivery performance across different models. Further development will involve continued internal research and potential collaborations to broaden the platform’s therapeutic applications.
“The liver was siRNA’s proving ground,” says Venkat Krishnamurthy, chief scientific officer of Genetic Medicines at Alloy Therapeutics. He explained that TEMPER is intended to build on that foundation by combining chemical approaches to improve stability and potency with targeting technologies designed to reach muscle, cardiac tissue, the CNS and other extrahepatic sites.
The TEMPER launch adds another technology to Alloy’s integrated RNA discovery offering, which already includes antisense oligonucleotide (ASO) development through its proprietary AntiClastic™ platform, as well as AOC capabilities.
By adding siRNA delivery to its existing capabilities, Alloy aims to provide partners with access to a wider range of technologies for designing, evaluating and optimizing RNA-based drug candidates. The expanded offering also draws on the company’s antibody discovery expertise and tissue-targeting technologies.
The broader strategy is to bring molecule design, delivery engineering and preclinical evaluation together within a single discovery framework, giving biotechnology and pharmaceutical partners additional options for advancing genetic medicine programs against targets that have been challenging to reach using conventional RNA delivery approaches.
For more information, visit alloytx.com/genetic-medicines/.
Total Page Views: 8

















